Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Allez

Showing results (101-110 of 205) with videos related to

Pageof 21
Sort By:
Inflammatory Bowel Diseases|December 1, 2011
Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel diseaseBenjamin Pariente, Guillaume Pineton de Chambrun, Roman Krzysiek, et al.
Inflammatory Bowel Diseases|January 9, 2007
Patchy distribution of mucosal lesions in ileal Crohn's disease is not linked to differences in the dominant mucosa-associated bacteria: a study using fluorescence in situ hybridization and temporal temperature gradient gel electrophoresisNadia Vasquez, Irène Mangin, Patricia Lepage, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 9, 2017
Autoimmune cytopenias associated with inflammatory bowel diseases: Insights from a multicenter retrospective cohortMathieu Uzzan, Lionel Galicier, Jean-Marc Gornet, et al.
Bulletin Du Cancer|January 23, 2015
Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancerJeanne Netter, Jacqueline Lehmann-Che, Jerome Lambert, et al.
Journal of Crohn'S & Colitis|October 6, 2017
European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel DiseaseGlen Doherty, Konstantinos H Katsanos, Johan Burisch, et al.
Gastroenterology|May 7, 2013
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trialJacques Cosnes, Anne Bourrier, David Laharie, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 8, 2020
COVID-19-Related IgA VasculitisMatthieu Allez, Blandine Denis, Jean-David Bouaziz, et al.
Frontiers in Cellular and Infection Microbiology|October 10, 2018
Prevalence of <i>Yersinia</i> Species in the Ileum of Crohn's Disease Patients and ControlsGuillaume Le Baut, Claire O'Brien, Paul Pavli, et al.
Clinics and Research in Hepatology and Gastroenterology|January 12, 2020
Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort studyNicolas Petitdidier, Laurent Beaugerie, Franck Carbonnel, et al.
Plos One|May 10, 2013
Specific IgG response against Mycobacterium avium paratuberculosis in children and adults with Crohn's diseaseJulien Verdier, Louis Deroche, Matthieu Allez, et al.
Pageof 21

Showing results (101-110 of 205) with videos related to

Sort By:
Pageof 21
Inflammatory Bowel Diseases|December 1, 2011
Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel diseaseBenjamin Pariente, Guillaume Pineton de Chambrun, Roman Krzysiek, et al.
Inflammatory Bowel Diseases|January 9, 2007
Patchy distribution of mucosal lesions in ileal Crohn's disease is not linked to differences in the dominant mucosa-associated bacteria: a study using fluorescence in situ hybridization and temporal temperature gradient gel electrophoresisNadia Vasquez, Irène Mangin, Patricia Lepage, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 9, 2017
Autoimmune cytopenias associated with inflammatory bowel diseases: Insights from a multicenter retrospective cohortMathieu Uzzan, Lionel Galicier, Jean-Marc Gornet, et al.
Bulletin Du Cancer|January 23, 2015
Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancerJeanne Netter, Jacqueline Lehmann-Che, Jerome Lambert, et al.
Journal of Crohn'S & Colitis|October 6, 2017
European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel DiseaseGlen Doherty, Konstantinos H Katsanos, Johan Burisch, et al.
Gastroenterology|May 7, 2013
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trialJacques Cosnes, Anne Bourrier, David Laharie, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 8, 2020
COVID-19-Related IgA VasculitisMatthieu Allez, Blandine Denis, Jean-David Bouaziz, et al.
Frontiers in Cellular and Infection Microbiology|October 10, 2018
Prevalence of <i>Yersinia</i> Species in the Ileum of Crohn's Disease Patients and ControlsGuillaume Le Baut, Claire O'Brien, Paul Pavli, et al.
Clinics and Research in Hepatology and Gastroenterology|January 12, 2020
Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort studyNicolas Petitdidier, Laurent Beaugerie, Franck Carbonnel, et al.
Plos One|May 10, 2013
Specific IgG response against Mycobacterium avium paratuberculosis in children and adults with Crohn's diseaseJulien Verdier, Louis Deroche, Matthieu Allez, et al.
Pageof 21